Search: WFRF:(Buonaguro FM)
> (2007-2009) >
DNA-VLP prime-boost...
DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity
-
- Buonaguro, L (author)
- Viral Oncogenesis and Immunotherapies & AIDS Reference Center, Italy
-
- Devito, C (author)
- Linköpings universitet,Molekylär virologi,Hälsouniversitetet
-
- Tornesello, ML (author)
- Viral Oncogenesis and Immunotherapies & AIDS Reference Center, Italy
-
show more...
-
- Schröder, U (author)
- Eurocine Vaccines AB, Sweden
-
- Wahren, B (author)
- Karolinska Institutet
-
- Hinkula, Jorma, 1958- (author)
- Linköpings universitet,Hälsouniversitetet,Molekylär virologi
-
- Buonaguro, FM (author)
- Viral Oncogenesis and Immunotherapies & AIDS Reference Center, Italy
-
show less...
-
(creator_code:org_t)
- Elsevier BV, 2007
- 2007
- English.
-
In: Vaccine. - : Elsevier BV. - 0264-410X .- 1873-2518. ; 25:32, s. 5968-5977
- Related links:
-
https://liu.diva-por... (primary) (Raw object)
-
show more...
-
http://liu.diva-port...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
show less...
Abstract
Subject headings
Close
- The immune response to HIV-1 virus-like particles (VLPs), presenting a clade A Ugandan gp120, has been evaluated in a mouse model by intra-nasal (i.n.) administration by a VLP + VLP homologous or a DNA + VLP heterologous prime-boost immunization protocol, including a HIV-1 DNA gp160/rev plasmid. Furthermore, the effect of the Eurocine lipid-based mucosal L3 adjuvant on the VLP immunogenicity has been assessed as well. The designed heterologous protocol is able to increase the env-specific humoral and cellular immune response, compared to the homologous protocol, which is to some extent increased by the administration of L3-adjuvanted VLP boosting dose. The anti-gag response is statistically increased in both homologous and heterologous protocols, particularly when the VLP boosting dose is adjuvanted. Immune sera from immunized animals exhibit >50% ex vivo neutralizing activity against heterologous A and B-clade viral isolates. An envelope B-cell epitope mapping shows an enhanced response against V3 epitopes all across the C2-V5 region in the heterologous prime-boost immunization strategy. The induction of humoral immunity at mucosal sites, which represents the main port of entry for the HIV-1 infection, is extremely relevant. In this framework, the DNA-VLP heterologous prime-boost protocol appears a promising preventive vaccine approach which can significantly benefit from specific mucosal adjuvants, as the Eurocine L3. © 2007 Elsevier Ltd. All rights reserved.
Keyword
- MEDICINE
- MEDICIN
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
-
Vaccine
(Search for host publication in LIBRIS)
To the university's database